Verge to share initial results from the Phase 1 trial of VRG50635 at the American Neurological Association Annual Meeting

We are pleased to share results from our Phase 1 clinical trial of VRG50635 at the American Neurological Association annual meeting on September 11. VRG50635 is a potential treatment for #ALS and one of the first drugs discovered & developed from an #AI-powered platform. #drugdiscovery #innovation #ANA2023